•  Retrait gratuit dans votre magasin Club
  •  7.000.000 titres dans notre catalogue
  •  Payer en toute sécurité
  •  Toujours un magasin près de chez vous     
  •  Retrait gratuit dans votre magasin Club
  •  7.000.000 titres dans notre catalogue
  •  Payer en toute sécurité
  •  Toujours un magasin près de chez vous

Mhc Class I Antigens in Malignant Cells

Immune Escape and Response to Immunotherapy

Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
Livre broché | Anglais | Springerbriefs in Cancer Research | n° 1
83,95 €
+ 167 points
Livraison 2 à 3 semaines
Passer une commande en un clic
Payer en toute sécurité
Livraison en Belgique: 3,99 €
Livraison en magasin gratuite

Description

Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. ​

Spécifications

Parties prenantes

Auteur(s) :
Editeur:

Contenu

Nombre de pages :
51
Langue:
Anglais
Collection :
Tome:
n° 1

Caractéristiques

EAN:
9781461465423
Date de parution :
22-02-13
Format:
Livre broché
Format numérique:
Trade paperback (VS)
Dimensions :
150 mm x 226 mm
Poids :
181 g

Les avis